Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025

Rhea-AI Summary

Co-Diagnostics (NASDAQ:CODX) announced its participation at WHX Kuala Lumpur, Southeast Asia's leading healthcare exhibition, from July 16-18, 2025 at MITEC. The event, expecting over 10,000 visitors from 54 countries, will serve as a platform for CODX to showcase its PCR diagnostics portfolio.

The company will promote its Co-Primers® technology and introduce its upcoming Co-Dx™ PCR platform, including the Co-Dx PCR MTB test and 8-plex Co-Dx HPV test, both scheduled for clinical evaluations later this year. The company's participation is partially supported by a grant from World Trade Center Utah.

SALT LAKE CITY, July 15, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at WHX (World Health Expo) Kuala Lumpur on July 16-18, 2025, at the Malaysia International Trade and Exhibition Centre (MITEC).

WHX Kuala Lumpur, formerly Asia Health/Medlab Asia, is the leading healthcare exhibition in Southeast Asia, providing networking and collaboration opportunities with industry leaders from across the globe. Event organizers have planned for more than 10,000 visitors from over 54 countries, discovering the latest technology and discussing future trends.  

The Company expects to use the opportunity to increase interest in its suite of PCR in vitro diagnostics for infectious diseases, to promote its Co-Primers® technology and applications, and to introduce its upcoming Co-Dx™ PCR platform*, including the Co-Dx PCR MTB test and the 8-plex Co-Dx HPV test, both of which remain on track to begin clinical evaluations later this year.

Attendees interested in learning more about the Company are invited to visit Booth L18. Details about the event can be found here.

Company travel and conference attendance is made possible due in part to a grant from World Trade Center Utah, a member of the World Trade Centers Association founded in 2006 with the goal of helping Utah companies increase revenue and create jobs by expanding international sales, attracting foreign investment, and facilitating international partnerships.

*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-whx-kuala-lumpur-on-july-16-18-2025-302505363.html

SOURCE Co-Diagnostics

FAQ

When and where is Co-Diagnostics (CODX) presenting at WHX Kuala Lumpur 2025?

Co-Diagnostics will be presenting at Booth L18 during WHX Kuala Lumpur from July 16-18, 2025 at the Malaysia International Trade and Exhibition Centre (MITEC).

What products will Co-Diagnostics (CODX) showcase at WHX Kuala Lumpur 2025?

CODX will showcase its PCR in vitro diagnostics for infectious diseases, Co-Primers® technology, and introduce its upcoming Co-Dx™ PCR platform, including the Co-Dx PCR MTB test and 8-plex Co-Dx HPV test.

How many visitors are expected at WHX Kuala Lumpur 2025?

The event organizers expect more than 10,000 visitors from over 54 countries to attend WHX Kuala Lumpur 2025.

When will Co-Diagnostics begin clinical evaluations for its new tests?

Co-Diagnostics plans to begin clinical evaluations for both the Co-Dx PCR MTB test and the 8-plex Co-Dx HPV test later in 2025.